Overview

Botulinum Toxin Urethral Sphincter Injection for Dysfunctional Voiding

Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
0
Participant gender:
All
Summary
This study is designed and aimed at determine the clinical efficacy of BoNT-A on patients with dysfunctional voiding. The results of this study can provide further information for patient selection and therapeutic duration.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Buddhist Tzu Chi General Hospital
Treatments:
abobotulinumtoxinA
Botulinum Toxins
Botulinum Toxins, Type A
incobotulinumtoxinA
onabotulinumtoxinA
Criteria
Inclusion Criteria:

- Adults with age of 20 years old or above.

- Free of active urinary tract infection.

- Free of bladder outlet obstruction on enrollment.

- Patients should have severe dysuria or urinary retention, large residual urine and
have been treated with medication or other therapeutic modality for over 3 months.

Exclusion Criteria:

- Patients with severe cardiopulmonary disease and such as congestive heart failure,
arrhythmia, poorly controlled hypertension, not able to receive regular follow-up.

- Patients with bladder outlet obstruction on enrollment.

- Patients with uncontrolled confirmed diagnosis of acute urinary tract infection.

- Patients have laboratory abnormalities at screening including: Alanine
aminotransferase (ALT) > 3 x upper limit of normal range aspartate aminotransferase
(AST) > 3 x upper limit of normal range.

- Patients have abnormal serum creatinine level > 2 x upper limit of normal range.

- Patients with any contraindication to be urethral catheterization during treatment.

- Female patients who is pregnant, lactating, or with child-bearing potential without
contraception.

- Patients with any other serious disease considered by the investigator not suitable
for general anesthesia or in the condition to enter the trial.

- Patients participated investigational drug trial within 1 month before entering this
study.

- Written informed consent has been obtained.